title: [Drug treatment of invasive aspergillosis of the paranasal sinuses].
abstract: Aspergillosis belongs to the group of mycotic diseases of the paranasal sinuses. The invasive forms, and particularly the fulminant forms, are potentially fatal. Primary surgical intervention with complete removal of the mycotic mass should be performed. Additionally an antimycotic drug therapy with amphotericin B must be started. In a review of the literature, there is no case surviving an extended invasive aspergillosis after failure of the operative therapy and after failure of the postoperative amphotericin B treatment. We report an interesting case of a complete remission of an invasive, partially fulminant aspergillosis of the paranasal sinuses and frontal and basal regions. After incomplete removal of the mycotic mass by an endo- and extranasal approach, we started postoperative drug therapy with amphotericin B. Under this treatment the mycosis progressed. Additionally the patient developed severe renal side effects requiring suspension of the treatment. At this time, we started a combined antimycotic drug therapy with liposomal amphotericin B (AmBisome) and itraconazol. Within 10 weeks there was complete clinical and radiologic remission. The patient died 63 weeks after this treatment because of a fulminant bacterial pneumonia. Post mortem examination showed no aspergillosis in the skull base, the paranasal sinuses, or in the lung. The question arises as to whether this drug combination of liposomal amphotericin B (AmBisome) and itraconazol is a real alternative to high-risk surgical interventions in this region.
authors.affiliation: Hals-Nasen-Ohren Klinik und Poliklinik der Univ. Köln.
authors.forename: M
authors.initials: M
authors.lastname: Streppel
authors.forename: E
authors.initials: E
authors.lastname: Stennert
authors.forename: K J
authors.initials: KJ
authors.lastname: Lackner
authors.forename: H E
authors.initials: HE
authors.lastname: Eckel
authors.forename: G
authors.initials: G
authors.lastname: Arnold
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005005:Ethmoid Sinus / Q000473:pathology / Q000601:surgery; D015521:Ethmoid Sinusitis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D014057:Tomography, X-Ray Computed
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B
vernacular_title: Medikamentöse Behandlung der invasiven Aspergillose der Nasennebenhöhlen.